OpportunityTitle: Therapeutics Development for HIV/AIDS-Associated Neuropsychological Disorders (SBIR[R43/R44])
AdditionalInformationOnEligibility: Foreign institutions are not eligible to apply. The NIH will accept as many &quot;different&quot; applications as the applicant organization chooses. However, the NIH will not accept similar grant applications with essentially the same research focus from the same applicant organization. This includes derivative or multiple applications that propose to develop a single product, process or service that, with non-substantive modifications, can be applied to a variety of purposes. Applicants may not simultaneously submit identical/essentially identical applications under both this funding opportunity and any other HHS FOA, including the current parent SBIR or STTR FOAs.
Description: This funding opportunity announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for the development of therapeutics to treat HIV/AIDS-associated mental and neurological disorders. The NIMH Center for Mental Health Research on AIDS (CMHRA) and NIDA encourage the discovery and development of novel agents, methods, biomarkers, and drug delivery technologies that can directly or indirectly eliminate/eradicate HIV reservoirs in the brain. Novel assays/models of neurotoxicity and treatment efficacy measures are invited as are novel in vitro/vivo models that can be used for screening potential therapeutic agents. This FOA also supports studies that examine agents or therapeutic strategies that protect/ameliorate/treat the long-term side effects of antiretroviral agents in the presence or absence of psychotropic medications, drugs of abuse, or medications to treat drug abuse. We additionally encourage the development of adjunctive therapies against the consequences of HIV in the CNS in the context of mental illness or drug addiction. -Budgets up to $250,000 total costs per year and time periods up to 2 years for Phase I may be requested. Budgets up to $450,000 total costs per year and up to 3 years may be requested for Phase II. -No funds have been specifically set aside for this program; the number of awards and the amount of funds provided for awards have not been predetermined. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-06-433 that solicits applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. -Eligible organizations: Only United States SBCs are eligible to submit SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III. -Eligible individuals: Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. On an SBIR application, the Project Director/Principal Investigator (PD/PI) must have his/her primary employment (more than 50%) with the SBC at the time of award and for the duration of the project. -Applicant SBCs may submit more than one application, provided each application is scientifically distinct.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster &lt;br/&gt;FBOWebmaster@OD.NIH.GOV &lt;br/&gt;
CloseDateExplanation: Multiple Receipt Dates - See Link to Full Announcement for details.